Resistance to linezolid (LZD) occurs through mutations in 23S rRNA and ribosomal proteins L3 and L4 or through methylation of 23S rRNA by Cfr. Here we report novel L3 mutations, ⌬Ser145/His146Tyr and ⌬Met169-Gly174, co-occurring with cfr in LZD-resistant Staphylococcus aureus isolates recovered from a hospital outbreak in Madrid, Spain. LZD MIC values (16, 32, or 64 g/ml) correlated with the presence and severity of the L3 mutation. All isolates had TR-700 (torezolid) MIC values of <2 g/ml.
Linezolid (LZD) resistance was first associated with mutations in the domain V region of 23S rRNA genes (G2576T) (7, 30) . Over time, a variety of 23S rRNA mutations have been identified, and these remain the most commonly reported class of mutation leading to LZD resistance (5, 9, 10) . In rare cases, mutations in ribosomal protein L4 have also been associated with LZD resistance (8, 17, 32) . More recently, a variety of mutations in ribosomal protein L3 have also been identified in both laboratory and clinically derived staphylococci associated with reduced susceptibility to oxazolidinones (15) (16) (17) . Cfrbased LZD resistance, however, is potentially more worrisome than mutation-based chromosomally encoded resistance mechanisms (25, 29) . The cfr gene encodes a methyltransferase which confers LZD resistance via methylation of carbon-8 on 23S rRNA base A2503 (6) . Cfr is generally plasmid borne and transposon associated and therefore likely to be horizontally transmitted (11) . Strains carrying cfr are resistant not only to LZD but also to phenicols, lincosamides, pleuromutilins, and streptogramin A class antibiotics (19) , as well as 16-membered ring macrolides (28) . Thus, selective pressure due to the use of any of these drug classes may lead to the spread of this resistance determinant.
The emergence of cfr and identification of additional LZD resistance mechanisms, including L3 mutations, raise the potential for multiple mechanisms to occur within a single strain. Our previous work identified coupled 23S rRNA and L3 mutations in both a laboratory LZD serially passaged Staphylococcus aureus strain (17) and a clinical Staphylococcus epidermidis isolate (15) . Another recent report documented a Spanish outbreak of LZD r strains (S. aureus, S. epidermidis, Enterococcus faecium, and Enterococcus faecalis) which included strains possessing cfr alone, 23S rRNA mutations alone, or 23S rRNA G2576T mutations in conjunction with cfr (2).
Finally, an outbreak of LZD r S. epidermidis in Ohio was comprised of isolates possessing an L4 mutation in conjunction with either the cfr gene or mutations in 23S rRNA (1) . These reports are the first to demonstrate the co-occurrence of cfr with any other LZD resistance mechanism; however, given the low fitness cost of Cfr methylation (12) , strains with resistance due to multiple mechanisms may not be unexpected. Characterization of such isolates and the evaluation of antibacterial activities of clinically relevant oxazolidinones are thus of high interest.
Previous reports of S. aureus cfr-positive clinical isolates and laboratory-generated cfr-transformed S. aureus strains typically cite LZD MIC values in the range of 8 to 16 g/ml (13, 14, 21, 29) . Analysis of cfr-positive LZD r MRSA from a 2008 hospital outbreak in Madrid, Spain, identified 18 isolates: 1 environmental and 12 patient intensive care unit (ICU) isolates, 3 patient isolates from other wards, and 2 additional patient isolates predating the outbreak that were identified in a retrospective study (22) . LZD MIC values for these strains were 8 (n ϭ 4), 16 (n ϭ 13), or 32 (n ϭ 1) g/ml (22) , all of which are above the LZD breakpoint of 4 g/ml. This study investigated whether additional oxazolidinone resistance mechanisms could account for the variability in LZD resistance levels among these clinical cfr isolates.
( MICs of clinically relevant oxazolidinones, LZD (ChemPacific, Inc., Baltimore, MD), TR-700 (torezolid, formerly known as DA-7157; Trius Therapeutics, Inc., San Diego, CA), and radezolid (RZD) (RX-1741; Medicilon, Chicago, IL), as well as tiamulin (TIA) (Wako Pure Chemical Industries, Ltd., Richmond, VA), chloramphenicol (CHL) (Sigma-Aldrich Corp., St. Louis, MO), and vancomycin (VAN) (Sigma), were determined via broth microdilution in accordance with CLSI guidelines as previously described (3, 17) . Quality control of oxazolidinones was performed via nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS), and biological activity assays. MIC values reported for each strain/drug combination were determined in at least three independent experiments, all yielding identical results. LZD MIC values for a panel of the 6 representative strains included in this study fell into three groups: group 1 (16 g/ml; n ϭ 1), group 2 (32 g/ml; n ϭ 4), or group 3 (64 g/ml; n ϭ 1), which corresponded to TR-700 MIC values of 0.5, 1, or 2 g/ml and radezolid MIC values of 4, 4, or 8 g/ml, respectively (Table 1) . Both TR-700 and LZD MIC values in this study were 2-fold higher than those originally reported for these strains (22) . As expected, the cfr isolates were resistant to TIA and CHL (Table 1).
The presence of additional ribosomal mutations was assessed by sequencing the domain V region of all 23S rRNA alleles and the genes encoding L3 (rplC) and L4 (rplD), as previously described (17, 20) . No ribosomal mutations were detected in the group 1 representative S. aureus isolate with an LZD MIC value of 16 g/ml (42262; pulsed-field gel electrophoresis [PFGE] type C) ( Table 1 ). The 4 group 2 isolates with LZD MIC values of 32 g/ml (32289, 56351, P-978 [environmental isolate], and 42292; PFGE A or B) all possessed the ⌬C434-C436 mutation in rplC, translating into a ⌬Ser145/ His146Tyr deletion/transversion mutation in L3. Strain 51312 (PFGE D), the only isolate with an LZD MIC of 64 g/ml (group 3), possessed a ⌬A505-T522 in-frame deletion in rplC, resulting in a 6-amino-acid ⌬Met169-Gly174 deletion in L3. The 2-to 4-fold TR-700 MIC shifts for strains with L3 mutations is consistent with previous reports of MIC shifts associated with L3 mutations (15, 17) , as is the TR-700 MIC of 0.5 g/ml against the cfr-only strain (18) . Radezolid demonstrates smaller fold shifts than LZD against a variety of ribosomal mutations (27) and against Cfr methylation; however, the presence of the acetamide results in 2-to 4-fold MIC increases (14) . Together these resistance mechanisms contribute to 4-to 8-fold-reduced susceptibility to radezolid versus strains possessing both Cfr and L3 resistance mechanisms.
Reduced susceptibility to oxazolidinones has been documented in S. aureus strains possessing mutations in some of the residues involved in these L3 mutations, including ⌬Ser145 (15, 16), Met169Leu/Gly155Arg (17), and ⌬Phe127-His146 (17). The precedence of similar L3 mutations in LZD r strains prompted us to investigate the newly identified mutants through analysis of the crystal structure of the Deinococcus radiodurans LZD-bound 50S subunit (PDB accession code 3DLL) (31) . The ⌬Ser145/ His146Tyr mutation abuts a cluster of 23S rRNA bases that include some known to influence those of the peptidyltransferase center (PTC) (e.g., G2576), therefore exerting its effect directly through a small set of intervening bases (Fig. 1) . The ⌬Met169-Gly174 mutation, although more distant from the PTC, involves the deletion of a significant strand of secondary structure (Fig. 1) . In order to accommodate this dramatic deletion, regions of the L3 protein proximal to the PTC must necessarily undergo large rearrangements. These perturbations are likely propagated to the adjacent PTC, resulting in the observed reduction in oxazolidinone binding.
In an effort to recapitulate and validate the coupled Cfr plus L3 resistance trends observed in these clinical isolates, we generated a panel of isogenic comparator strains in the S. aureus ATCC 29213 background. The wild-type ATCC 29213 parent strain and three isogenic, laboratory-selected L3 mutants (17) having two different oxazolidinone susceptibility profiles were transformed with the p42262 cfr plasmid (isolated from clinical strain 42262) (23) via electroporation as previously described (24) . Transformant MICs mirrored the oxazolidinone MICs observed in the clinical strains, suggesting that the Cfr and Cfr plus L3-based resistance mechanisms are the primary contributing factors to the observed LZD resistance levels in these clinical isolates. Based on the structural analyses and MIC trends from cfr-transformed 29213 L3 mu- tants, the difference in LZD resistance levels (i.e., 32 versus 64 g/ml) among some of these clinical strains is likely due to differences in how severely each L3 mutation perturbs the PTC and thus reduces oxazolidinone binding affinity. Novel mutations in ribosomal protein L3 were detected in each of the S. aureus cfr isolates examined with LZD MIC values of Ͼ16 g/ml. TR-700 was the only oxazolidinone tested with MIC values of Յ2 g/ml against all strains. Because the breakpoints for TR-700 and radezolid have not been determined, the clinical relevance of MIC values against these strains cannot yet be assessed. Enhanced activity of TR-700 is primarily due to reduced steric hindrance of the TR-700 C-5 hydroxymethyl substituent compared to the acetamide of LZD or radezolid in the presence of Cfr methylation (14, 26) . This study is the first to document the co-occurrence of cfr in clinical S. aureus isolates possessing L3 mutations, following reports of cfr coupled with 23S rRNA (2) or L4 (1) mutation-based resistance mechanisms. Cfr methylation has now been shown to be compatible with each of the three documented classes of mutation-based staphylococcal resistance to LZD, thus highlighting the need for next-generation oxazolidinones to maintain activity against a variety of resistance mechanisms.
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ADDENDUM IN PROOF
During the review process of this manuscript, work documenting the co-occurence of the cfr gene in clinical Staphylococcus aureus isolates possessing L3 mutations was published (R. E. Mendes, L. Deshpande, E. Rodriguez-Noriega, J. E. 
